急诊科青少年性侵受害者STI阳性后暴露后预防处方取药率
该单中心回顾性描述性研究纳入2022年3月至2024年9月急诊科就诊的0-17岁性侵评估患者459例,其中41.6%为青少年,8.5%淋病/衣原体检测阳性。31例STI阳性青少年出院时23例(74.2%)接受适当PEP;17例在急诊开处方者中12例(70.6%)取药,10例(58.8%)开始服药,6例(35.3%)完成疗程。结论认为取药率不理想,需针对该脆弱人群的依从性干预。
要点
- 青少年性侵后淋病/衣原体PEP需7天抗生素疗程并开处方,本研究中STI阳性出院青少年仅74.2%接受适当PEP。
- 在急诊开PEP处方的17例中,取药率70.6%,开始服药率58.8%,完成疗程率仅35.3%。
- 总体459例性侵评估患者中8.5%淋病/衣原体阳性,其中34例为青少年。
- 需对出院带处方PEP的青少年性侵受害者进行取药和服药依从性随访干预。
适用人群与场景
- 0-17岁在儿科急诊(PED)因急性性侵评估就诊的患者;其中12-17岁青少年为PEP处方取药率分析人群。
- STI阳性(淋病、衣原体或两者)的青少年患者,出院时接受PEP处方者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 对淋病、衣原体和滴虫推荐暴露后预防;鉴于抗生素耐药,指南推荐衣原体和滴虫预防给予7天抗生素疗程,需开处方(原文未提及具体药名、剂量、途径)。
- 对STI阳性患者进行电话随访(原文未提及随访具体内容)。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:单中心、回顾性、描述性研究;样本量459例(0-17岁性侵评估患者),其中41.6%为青少年,82.1%女性,44.4%西班牙裔/拉丁裔。
- 39例(8.5%)淋病/衣原体阳性,其中34例为青少年;31例STI阳性出院青少年中23例(74.2%)接受淋病、衣原体和滴虫适当预防。
- 17例在急诊开PEP处方且有处方结局记录者中,12例(70.6%)取药,10例(58.8%)开始服药,6例(35.3%)完成服药。
证据类型、等级与局限
- 证据类型:回顾性、单中心、描述性研究;原文未给出证据等级或推荐强度。
- 局限:单中心、回顾性设计、样本量小(尤其处方结局仅17例)、描述性统计,无法推断因果关系。
对床旁实践的改变
- 提示急诊对青少年性侵后STI阳性者开PEP处方后,需关注取药和服药完成情况,本研究中完成疗程率仅35.3%。
- 适用人群:12-17岁性侵后STI阳性青少年;不适用人群:原文未提及。
- 常见陷阱:仅开处方不等于治疗完成,需随访确认取药、启动和完成疗程。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Child sexual assault is a significant public health issue associated with potentially devastating physical and psychological consequences, including risk of sexually transmitted infections (STI). Post-exposure prophylaxis for gonorrhea, chlamydia, and trichomonas is recommended for adolescent patients. Given ongoing antibiotic resistance, guidelines recommend a 7-day course of antibiotics be given for prophylaxis against chlamydia and trichomonas, requiring prescriptions. We describe the pediatric population seen for acute sexual assault in the pediatric emergency department (PED) as well as prescription fill rates in adolescents who are positive for STI.
METHODS: A retrospective, single center, descriptive study of STI rates of patients, 0-17 years of age, as well as post-exposure prophylaxis (PEP) prescription fill rates of adolescent patients 12-17 years of age seen in the PED for evaluation of pediatric sexual assault from March 1, 2022 - Sept 1, 2024. A follow-up phone call was conducted on all patients positive for STIs. Data was obtained from a secure database maintained by the Sexual Assault Nurse Examiner (SANE) team and analyzed using descriptive and inferential statistical methods to assess prescription fill rates and associated demographic variables.
RESULTS: Of the total 459 patients seen for sexual assault evaluation, 41.6% were adolescents, 82.1% were female, and 44.4% were Hispanic/Latino. Overall, 39 (8.5%) patients tested positive for gonorrhea, chlamydia, or both; of these, 34 were adolescents. Of the 31 adolescent patients with an STI who were discharged, 23 (74.2%) received appropriate prophylaxis for gonorrhea, chlamydia, and trichomonas. Of the 17 patients who received prescriptions in the PED with known prescription outcomes, 12 (70.6%) filled their prescriptions, 10 (58.8%) started their medications, and 6 (35.3%) completed their medications.
CONCLUSION: Our population had sub-optimal prescription fill rates, which is concerning given the consequences of untreated STIs. This study aims to provide data as a starting point to guide future interventions to improve prescription adherence in this vulnerable population.
参考来源
- Henin S, Gefke I, Ferrell J, et al. Post-exposure prophylaxis prescription fill rate among STI-positive adolescent sexual assault patients in the emergency department. Am J Emerg Med. 2026. PMID: 42526298. doi:10.1016/j.ajem.2026.07.041
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。